New data on proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors, which dramatically affect low density lipoprotein (LDL) cholesterol as well as other blood lipids, are creating a paradigm shift in how one manages LDL-lowering in difficult-to-treat patients (eg, patients with familial hypercholesterolemia, patients with statin intolerance). In this video webcast, Jennifer G. Robinson, MD, MPH, poses and answers critical questions about PCSK9 inhibitors, including mechanisms of action, efficacy and safety profiles, and the therapeutic potential for patients with unmet cardiopreventive needs.

Faculty

Jennifer G. Robinson, MD, MPH
Professor, Departments of Epidemiology and Medicine (Division of Cardiology)
Director, Prevention Intervention Center
University of Iowa
Iowa City, Iowa

Target audience

This activity was developed for cardiologists and other health care professionals involved in the care of patients at high risk for cardiovascular disease morbidity and mortality.

Learning objectives

At the conclusion of this activity, participants should be better able to:

• Discuss the emerging role of PCSK9 inhibition in preventive cardiology, specifically in patients at high risk for cardiovascular disease
• Compare and contrast the efficacy/tolerability profile data, mechanism of action, and administration of emerging PCSK9 inhibitors
• Identify patients who have unmet cardiopreventive needs and who might benefit from novel, LDL-lowering therapeutic agents

Instructions

Complete these 3 easy steps to participate in this activity:

1) Complete the pre-activity Clinical Impact Challenge quiz, which will allow you to compare your answers at the beginning of the activity to your post-activity answers.

2) Watch the video webcast by Dr. Robinson.

3) Complete the post-activity quiz and evaluation form. You can claim credit and receive your certificate once you have passed the quiz and completed the evaluation.

This activity is supported by an educational donation provided by Amgen.